Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Short Interest Report for September

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 2,864,201 shares, an increase of 76.1% from the September 15th total of 1,626,351 shares. Currently, 21.1% of the company’s stock are sold short. Based on an average trading volume of 8,031,092 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Investors Weigh In On Vivos Therapeutics

A hedge fund recently bought a new position in Vivos Therapeutics stock. Sequoia Financial Advisors LLC purchased a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned about 0.18% of Vivos Therapeutics as of its most recent filing with the Securities & Exchange Commission. 26.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $2.80.

Vivos Therapeutics Trading Up 6.6%

Shares of Vivos Therapeutics stock opened at $0.14 on Friday. The firm has a fifty day simple moving average of $0.20 and a 200-day simple moving average of $0.52. Vivos Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.21. The stock has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.08 and a beta of 6.11.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.10. The business had revenue of $5.15 million during the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. As a group, research analysts predict that Vivos Therapeutics will post -1.24 earnings per share for the current year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep.

The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep.